Biologics, Biosimilars, and Interchangeable Biologics: Considerations with the Entrance of Biosimilar Products in the U.S.

Science & Innovation Theater Webinar 

Recorded on September 11, 2015 

Sponsored by Janssen 


Please join Janssen and healthcare advisory firm Avalere Health for an in-depth conversation on the biosimilars landscape. 

The webinar will include discussion of the scientific, regulatory, and legal issues, to help explain why the U.S. has yet to see biosimilars routinely available to prescribers and patients. The presentation will be led by Dr. Jay Siegel, Chief Biotechnology Officer at Johnson & Johnson, and Dr. Scott Gottlieb, Senior Advisor at Avalere Health. They will review recent developments in the U.S. and provide perspective on the future landscape for biologics, biosimilars, and interchangeable biologics.

This presentation is suitable for all  audiences, and will include a questions and answers portion.


  • Dr. Jay Siegel, Johnson & Johnson
  • Dr. Scott Gottlieb, Avalere Health
  • Dr. Brenda Huneycutt, Avalere Health


  • Steve Usdin, BioCentury Publications Inc

Sponsored by: 

Janssen Logo 



(C) Janssen Biotech Inc. 2015 (08/15)                                                                                                                                                   040311-150914

This promotional educational activity is not accredited. The program content is developed by Janssen Biotech, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.  

This webinar is sponsored, developed and presented by the sponsor. The content of the Science & Innovation Theater Webinars and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy.